Approval · Notice of Compliance 16607 · 2015
FRAGMIN: Notice of Compliance 16607
Issued February 16, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16607
- Date
- February 16, 2015
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New manufacturing site
- Therapeutic class
- Anticoagulant, antithrombotic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FRAGMIN | Not yet assigned | — |
Medicinal ingredients
- DALTEPARIN SODIUM 2,500 UNIT per ML
- DALTEPARIN SODIUM 10,000 UNIT per ML
- DALTEPARIN SODIUM 2,500 UNIT per 0.2ML
- DALTEPARIN SODIUM 5,000 UNIT per 0.2ML
- DALTEPARIN SODIUM 25,000 UNIT per ML